Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Connection

Michael Bristow to Heart Rate

This is a "connection" page, showing publications Michael Bristow has written about Heart Rate.

 
Connection Strength
 
 
 
0.814
 
  1. Pittenger B, Gill EA, Holcslaw TL, Bristow MR. Relation of dose of carvedilol to reduction in QT dispersion in patients with mild to moderate heart failure secondary to ischemic or to idiopathic dilated cardiomyopathy. Am J Cardiol. 2004 Dec 01; 94(11):1459-62.
    View in: PubMed
    Score: 0.183
  2. Bristow MR, Altman NL. Heart Rate in Preserved Ejection?Fraction?Heart Failure. JACC Heart Fail. 2017 11; 5(11):792-794.
    View in: PubMed
    Score: 0.112
  3. Leary PJ, Bristow MR. Reply: Is Histamine H2 Receptor a Real?Promising Target for Prevention or?Treatment?of Heart Failure? J Am Coll Cardiol. 2016 11 01; 68(18):2029-2030.
    View in: PubMed
    Score: 0.105
  4. Kao DP, Davis G, Aleong R, O'Connor CM, Fiuzat M, Carson PE, Anand IS, Plehn JF, Gottlieb SS, Silver MA, Lindenfeld J, Miller AB, White M, Murphy GA, Sauer W, Bristow MR. Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation. Eur J Heart Fail. 2013 Mar; 15(3):324-33.
    View in: PubMed
    Score: 0.080
  5. Bullinga JR, Alharethi R, Schram MS, Bristow MR, Gilbert EM. Changes in heart rate variability are correlated to hemodynamic improvement with chronic CARVEDILOL therapy in heart failure. J Card Fail. 2005 Dec; 11(9):693-9.
    View in: PubMed
    Score: 0.049
  6. Lowes BD, Tsvetkova T, Eichhorn EJ, Gilbert EM, Bristow MR. Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol. Int J Cardiol. 2001 Dec; 81(2-3):141-9.
    View in: PubMed
    Score: 0.037
  7. Lindenfeld J, Lowes BD, Bristow MR. Hypotension with dobutamine: beta-adrenergic antagonist selectivity at low doses of carvedilol. Ann Pharmacother. 1999 Dec; 33(12):1266-9.
    View in: PubMed
    Score: 0.032
  8. Gwathmey JK, Kim CS, Hajjar RJ, Khan F, DiSalvo TG, Matsumori A, Bristow MR. Cellular and molecular remodeling in a heart failure model treated with the beta-blocker carteolol. Am J Physiol. 1999 05; 276(5):H1678-90.
    View in: PubMed
    Score: 0.031
  9. Shakar SF, Abraham WT, Gilbert EM, Robertson AD, Lowes BD, Zisman LS, Ferguson DA, Bristow MR. Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure. J Am Coll Cardiol. 1998 May; 31(6):1336-40.
    View in: PubMed
    Score: 0.029
  10. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation. 1996 Dec 01; 94(11):2807-16.
    View in: PubMed
    Score: 0.026
  11. Gilbert EM, Abraham WT, Olsen S, Hattler B, White M, Mealy P, Larrabee P, Bristow MR. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation. 1996 Dec 01; 94(11):2817-25.
    View in: PubMed
    Score: 0.026
  12. Quaife RA, Gilbert EM, Christian PE, Datz FL, Mealey PC, Volkman K, Olsen SL, Bristow MR. Effects of carvedilol on systolic and diastolic left ventricular performance in idiopathic dilated cardiomyopathy or ischemic cardiomyopathy. Am J Cardiol. 1996 Oct 01; 78(7):779-84.
    View in: PubMed
    Score: 0.026
  13. Metra M, Eichhorn E, Abraham WT, Linseman J, B?hm M, Corbalan R, DeMets D, De Marco T, Elkayam U, Gerber M, Komajda M, Liu P, Mareev V, Perrone SV, Poole-Wilson P, Roecker E, Stewart J, Swedberg K, Tendera M, Wiens B, Bristow MR. Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials. Eur Heart J. 2009 Dec; 30(24):3015-26.
    View in: PubMed
    Score: 0.016
  14. Shaddy RE, Mak C, Bristow MR. Comparative in vitro myocardial inotropic effects and in vivo hemodynamic effects of forskolin and isoproterenol in young lambs. Pediatr Res. 1989 Jun; 25(6):580-4.
    View in: PubMed
    Score: 0.016
  15. Anderson FL, Kralios AC, Hershberger R, Bristow MR. Effect of vasoactive intestinal peptide on myocardial contractility and coronary blood flow in the dog: comparison with isoproterenol and forskolin. J Cardiovasc Pharmacol. 1988 Sep; 12(3):365-71.
    View in: PubMed
    Score: 0.015
  16. Schleman KA, Lindenfeld JA, Lowes BD, Bristow MR, Ferguson D, Wolfel EE, Abraham WT, Zisman LS. Predicting response to carvedilol for the treatment of heart failure: a multivariate retrospective analysis. J Card Fail. 2001 Mar; 7(1):4-12.
    View in: PubMed
    Score: 0.009
  17. Bristow MR, Sageman WS, Scott RH, Billingham ME, Bowden RE, Kernoff RS, Snidow GH, Daniels JR. Acute and chronic cardiovascular effects of doxorubicin in the dog: the cardiovascular pharmacology of drug-induced histamine release. J Cardiovasc Pharmacol. 1980 Sep-Oct; 2(5):487-515.
    View in: PubMed
    Score: 0.009
  18. Schroeder JS, Beier-Scott L, Ginsburg R, Bristow MR, McAuley BJ. Efficacy of diltiazem for medically refractory stable angina: long-term follow-up. Clin Cardiol. 1985 Sep; 8(9):480-5.
    View in: PubMed
    Score: 0.003
  19. Clusin WT, Bristow MR, Baim DS, Schroeder JS, Jaillon P, Brett P, Harrison DC. The effects of diltiazem and reduced serum ionized calcium on ischemic ventricular fibrillation in the dog. Circ Res. 1982 Apr; 50(4):518-26.
    View in: PubMed
    Score: 0.002
  20. Clusin WT, Bristow MR, Karagueuzian HS, Katzung BG, Schroeder JS. Do calcium-dependent ionic currents mediate ischemic ventricular fibrillation? Am J Cardiol. 1982 Feb 18; 49(3):606-12.
    View in: PubMed
    Score: 0.002
  21. Ginsburg R, Bristow MR, Kantrowitz N, Baim DS, Harrison DC. Histamine provocation of clinical coronary artery spasm: implications concerning pathogenesis of variant angina pectoris. Am Heart J. 1981 Nov; 102(5):819-22.
    View in: PubMed
    Score: 0.002
  22. Mason JW, Bristow MR, Billingham ME, Daniels JR. Invasive and noninvasive methods of assessing adriamycin cardiotoxic effects in man: superiority of histopathologic assessment using endomyocardial biopsy. Cancer Treat Rep. 1978 Jun; 62(6):857-64.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)